Income Taxes - Narrative (Details) - USD ($) |
12 Months Ended | |
|---|---|---|
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Operating Loss Carryforwards [Line Items] | ||
| Net change in valuation allowance | $ 1,244,274 | $ 3,100,898 |
| Deferred Tax Assets, Capitalized Research and Development Expenses | 1,524,035 | 1,873,211 |
| Capitalized research and development expenses | 1,728,078 | $ 8,099,702 |
| U.S. Federal | ||
| Operating Loss Carryforwards [Line Items] | ||
| Net operating loss carryforwards | 26,496,000 | |
| Georgia | State and local jurisdiction | ||
| Operating Loss Carryforwards [Line Items] | ||
| Net operating loss carryforwards | 33,700,000 | |
| Florida | State and local jurisdiction | ||
| Operating Loss Carryforwards [Line Items] | ||
| Net operating loss carryforwards | $ 851,086 | |
| X | ||||||||||
- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of research and development expenses capitalized. No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|